Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

Summary

The purpose of this study is to evaluate an ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

Timeline

Start

2013-01

Primary completion

2013-07

Completion

2013-07

Outcome

Met primary endpoint

paper Olopatadine 0.77% was superior to the vehicle at alleviating ocular itching PMID 26266427 ↗

paper P < 0.0001 PMID 26266427 ↗

Publications

• Carr W, Schaeffer J, Donnenfeld E. Treating allergic conjunctivitis: A once-daily medication that provides 24-hour symptom relief. Allergy Rhinol (Providence). 2016 Jan;7(2):107-14. doi: 10.2500/ar.2016.7.0158. Epub 2016 Jul 26.
• McLaurin E, Narvekar A, Gomes P, Adewale A, Torkildsen G. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model. Cornea. 2015 Oct;34(10):1245-51. doi: 10.1097/ICO.0000000000000562.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olopatadine	Other / unclassified	0.1 %	Topical
Subject	Olopatadine	Other / unclassified	0.2 %	Topical
Subject	Olopatadine	Other / unclassified	0.77 %	Topical

Indications